SciELO - Scientific Electronic Library Online

1. Spector SA. Factors impacting on drug choices. Issues for developing countries. Annals of the New York Academy of Sciences, 2000, 918: 346–350.

2. Cohen J. AIDS meeting. Companies, donors pledge to close gap in AIDS treatment. Science, 2000, 289: 368–369.

3. Individual members of the Faculty of Harvard University. Consensus statement on antiretroviral treatment for AIDS in poor countries. Topics in HIV Medicine, 2001, 9: 14–26.

4. The world factbook 2000. Central Intelligence Agency (accessed on 20 August 2001 at http://www.odci.gov/cia/publications/factbook/ha.html).

5. Piot P. Global AIDS epidemic: time to turn the tide. Science, 2000, 288: 2176–2178.

6. Bloom DE. Something to be done: treating HIV/AIDS. River Path Associates. Science, 2000, 288: 2171–2173.

7. Farmer PE, Walton DA, Furin JJ. The changing face of AIDS: implications for policy and practice. In: Mayer K, Pizer H, eds. The emergence of AIDS: the impact on immunology, microbiology, and public health. Washington, DC, American Public Health Association, 2000.

8. El Sony AI et al. Tuberculosis control in Sudan against seemingly insurmountable odds. International Journal of Tuberculosis and Lung Disease, 2000, 4: 657–664.

9. Del Mistro A, Chieco Bianchi L. HPV-related neoplasias in HIV- infected individuals. European Journal of Cancer, 2000, 37: 1227–1235.

10. Madhi SA et al. Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children. Clinical Infectious Diseases, 2000, 31: 170–176.

11. Sibanda A. A nation in pain: why the HIV/AIDS epidemic is out of control in Zimbabwe. International Journal of Health Services, 2000, 30: 717–738.

12. Floyd K et al. Admission trends in a rural South African hospital during the early years of the HIV epidemic. JAMA, 1999, 282: 1087–1091.

13. Low-Beer D, Stoneburner RL, Mukulu A. Empirical evidence for the severe but localized impact of AIDS on population structure. Nature Medicine, 1997, 3: 553–557.

14. Farmer P. Social inequalities and emerging infectious diseases. Emerging Infectious Diseases, 1996, 4: 259–269.

15. Accorsi S et al. Impact of insecurity, the AIDS epidemic, and poverty on population health: disease patterns and trends in Northern Uganda. American Journal of Tropical Medicine and Hygiene, 2001, 64: 214–221.

16. Butler C. HIV and AIDS, poverty, and causation. Lancet, 2000, 356: 1445–1446.

17. Basu S, Mate K, Farmer, PE. Debt and poverty turn a disease into an epidemic. Nature, 2000, 407: 13.

18. Kandela P. Child prostitution and the spread of AIDS. Lancet, 2000, 356: 1991.

19. Beyrer C. Burma and Cambodia: human rights, social disruption, and the spread of HIV/AIDS. Health and Human Rights, 1998, 2: 84–97.

20. Farmer P, Connors M, Simmons J, eds. Women, poverty, and AIDS: sex, drugs, and structural violence. Monroe, ME, Common Courage Press, 1996.

21. O'Leary A, Martins P. Structural factors affecting women's HIV risk: a life-course example. AIDS, 2000, 14 (Suppl. 1): S68–S72.

22. Luo C. Achievable standard of care in low-resource settings. Annals of the New York Academy of Sciences, 2000, 918: 179–187.

23. Wilkinson D, Floyd K, Gilks CF. National and provincial estimated costs and cost effectiveness of a programme to reduce mother-to-child HIV transmission in South Africa. South African Medical Journal, 2000, 90: 794–798.

24. Dayton JM, Merson MH. Global dimensions of the AIDS epidemic: implications for prevention and care. Infectious Disease Clinics of North America, 14: 791–808.

25. Rogers MF, Stockton PL. Organizational approaches to the HIV/AIDS crisis. Annals of the New York Academy of Sciences, 2000, 918: 188–194.

26. Kapiga SH et al. Predictors of AIDS knowledge, condom use and high risk sexual behaviour among women in Dar-es-Salaam, Tanzania. International Journal of STD & AIDS, 1995, 6: 175–183.

27. Takyi BK. AIDS-related knowledge and risks and contraceptive practices in Ghana: the early 1990s. African Journal of Reproductive Health, 2000, 4: 13–27.

28. Mayaud P, Hawkes S, Mabey D. Advances in control of sexually transmitted disease in developing countries. Lancet, 1998, 351 (Suppl. 3): 29–32.

29. HIV/AIDS surveillance report. Vol. 11, No. 2. Atlanta, GA, Centers for Disease Control and Prevention, 1999.

30. Attaran A, Sachs J. Defining and refining international donor support for combating the AIDS pandemic. Lancet, 2001, 357: 57–61.

31. Donnelly J. Policy on AIDS in Africa debated, leaders say prevention should be the focus. The Boston Globe, 7 April 2001.

32. Costs of antiretroviral drugs in Brazil (1996–2000). Ministry of Health, Brazil, 2000 (accessed on 7 November 2001 at http://www.aids.gov.br/assistencia/costs_antiretroviral_drugs_brazil.htm).

33. Kahn J. Rich nations consider fund of billions to fight AIDS. New York Times, 29 April 2001: 10.

34. Colebunders R et al. Impact of new developments in antiretroviral treatment on AIDS prevention and care in resource- poor countries. AIDS Patient Care and STDs, 2000, 14: 251–257.

35. De Cock KM. Tuberculosis control in resource-poor settings with high rates of HIV infection. American Journal of Public Health, 1996, 86 (8 Part 1): 1071–1073.

36. Report on the global HIV/AIDS epidemic, June 2000. Geneva, UNAIDS, 2000 (unpublished document UNAIDS/00.13E).

37. Pape J, Johnson WD. AIDS in Haiti: 1982–1992.Clinical Infectious Diseases, 1993, 17 (Suppl. 2): S341–S345.

38. Chaisson RE, Coberly JS, De Cock KM. DOTS and drug resistance: a silver lining to a darkening cloud. International Journal of Tuberculosis and Lung Disease, 1999, 3: 1–3.

39. Farmer PE. Letter from Haiti. AIDS Clinical Care, 1997, 9: 83–85.

40. Farmer PE et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet, 2001, 358: 404–409.

41. Farmer PE, Walton DA. Condoms, coups, and the ideology of prevention: facing failure in rural Haiti. In: Keenan J, ed. Catholic ethicists in HIV/AIDS prevention. Maryknoll, NY, Orbis Books, 2000.

42. Lockman S et al. Molecular and conventional epidemiology of Mycobacterium tuberculosis in Botswana: a population- based prospective study of 301 pulmonary tuberculosis patients. Journal of Clinical Microbiology, 2001, 39: 1042–1047.

43. Paterson DL et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 2000, 133: 21–30.

44. Brouwer CN et al. Psychosocial and economic aspects of HIV/AIDS and counselling of caretakers of HIV-infected children in Uganda. AIDS Care, 2000, 12: 535540.

45. McNeil DG. Selling cheap `generic' drugs, India's copycats irk industry. New York Times, 1 December 2000: 1(A).

46. Gellman B. An unusual calculus of life and death; as millions perished in pandemic, firms debated access to drugs; players in the debate over drug availability and pricing. Washington Post, 16 December 2000, Section A: 1.

47. Freedberg KA et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. New England Journal of Medicine, 2000, 344: 824–831.

48. Pérez-Casas P et al. HIV/AIDS medicines pricing report. Setting objectives: is there a political will? Access to Essential Medicines Campaign, Médecins Sans Frontières, 6 July 2000.

49. Rifampicin or ethambutol in the routine treatment of tuberculosis. British Medical Journal, 1973, 4: 568 [editorial].

50. Gupta R et al. Responding to market failures in tuberculosis control. Science, 2001, 293: 1049–1051.

51. Farmer PE. The major infectious diseases in the world — to treat or not to treat? New England Journal of Medicine, 2001, 345: 208–210.